Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on Equity

Inhibikase Therapeutics (IKT) Debt Ratio (2020 - 2025)

Inhibikase Therapeutics (IKT) has disclosed Debt Ratio for 6 consecutive years, with 0.0 as the latest value for Q2 2025.

  • Quarterly Debt Ratio fell 97.52% to 0.0 in Q2 2025 from the year-ago period, while the trailing twelve-month figure was 0.0 through Jun 2025, down 97.52% year-over-year, with the annual reading at 0.0 for FY2024, 89.17% down from the prior year.
  • Debt Ratio for Q2 2025 was 0.0 at Inhibikase Therapeutics, down from 0.0 in the prior quarter.
  • The five-year high for Debt Ratio was 0.03 in Q3 2024, with the low at 0.0 in Q2 2025.
  • Average Debt Ratio over 5 years is 0.01, with a median of 0.01 recorded in 2022.
  • The sharpest move saw Debt Ratio skyrocketed 298.06% in 2024, then plummeted 97.52% in 2025.
  • Over 5 years, Debt Ratio stood at 0.01 in 2021, then grew by 15.64% to 0.01 in 2022, then surged by 76.92% to 0.01 in 2023, then tumbled by 89.17% to 0.0 in 2024, then plummeted by 61.9% to 0.0 in 2025.
  • According to Business Quant data, Debt Ratio over the past three periods came in at 0.0, 0.0, and 0.0 for Q2 2025, Q1 2025, and Q4 2024 respectively.